Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: A cooperation task force (CTF) study

Angiolo Gadducci, Stefania Cosio, Fabio Landoni, Tiziano Maggino, Paolo Zola, Luca Fuso, Enrico Sartori

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To assess the pattern of failures and the survival of patients with uterine papillary serous carcinoma (UPSC). Methods: The hospital records of 119 women with UPSC were reviewed. Surgery was the initial therapy for all the cases. The median follow-up of survivors was 133 months (range, 3Y216 months). Results: Postoperative treatment was used in 98 patients (82.4%). Adjuvant treatment was radiotherapy in 25 women, chemotherapy in 61 women, and chemotherapy plus radiotherapy in 12 women. Tumor recurred in 44 (37.0%) of the 119 patients, after a median time of 15.1 months. Relapse was symptomatic in 15 patients (34.1%), and recurrent disease involved peritoneum or distant sites in 26 (66.7%) of the 39 patients for whom the site of failure was known. Five- and 10-year survival rates were 61.8% and 54.6%, respectively. Survival was related to disease stage (P G 0.0001). Among patients with advanced tumor, 5-year survival was lower in women who had macroscopic residual disease after surgery than in those who had not (15.4% vs 37.5%; P = 0.08). Distant failures were higher in women with histologically proven positive nodes than in those with negative nodes (28.6% vs 9.1%; P = 0.048). There was a trend to better survival for patients with stage I to stage II disease who underwent chemotherapy when compared with those who did not. Conclusions: Uterine papillary serous carcinoma has an aggressive clinical behavior with a great tendency to recur especially in peritoneal and distant sites. Tumor stage is a strong prognostic factor, whereas the role of adjuvant treatment is still uncertain.

Original languageEnglish
Pages (from-to)1355-1360
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume22
Issue number8
DOIs
Publication statusPublished - 2012

Fingerprint

Papillary Carcinoma
Advisory Committees
Treatment Failure
Survival
Drug Therapy
Radiotherapy
Neoplasms
Hospital Records
Peritoneum
Therapeutics
Survivors
Survival Rate
Recurrence

Keywords

  • Chemotherapy
  • Pattern of failure
  • Radiotherapy
  • Surgical staging
  • Uterine papillary serous carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma : A cooperation task force (CTF) study. / Gadducci, Angiolo; Cosio, Stefania; Landoni, Fabio; Maggino, Tiziano; Zola, Paolo; Fuso, Luca; Sartori, Enrico.

In: International Journal of Gynecological Cancer, Vol. 22, No. 8, 2012, p. 1355-1360.

Research output: Contribution to journalArticle

Gadducci, Angiolo ; Cosio, Stefania ; Landoni, Fabio ; Maggino, Tiziano ; Zola, Paolo ; Fuso, Luca ; Sartori, Enrico. / Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma : A cooperation task force (CTF) study. In: International Journal of Gynecological Cancer. 2012 ; Vol. 22, No. 8. pp. 1355-1360.
@article{6e40d7fb52b5428091aa3e76d5fc570f,
title = "Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: A cooperation task force (CTF) study",
abstract = "Objective: To assess the pattern of failures and the survival of patients with uterine papillary serous carcinoma (UPSC). Methods: The hospital records of 119 women with UPSC were reviewed. Surgery was the initial therapy for all the cases. The median follow-up of survivors was 133 months (range, 3Y216 months). Results: Postoperative treatment was used in 98 patients (82.4{\%}). Adjuvant treatment was radiotherapy in 25 women, chemotherapy in 61 women, and chemotherapy plus radiotherapy in 12 women. Tumor recurred in 44 (37.0{\%}) of the 119 patients, after a median time of 15.1 months. Relapse was symptomatic in 15 patients (34.1{\%}), and recurrent disease involved peritoneum or distant sites in 26 (66.7{\%}) of the 39 patients for whom the site of failure was known. Five- and 10-year survival rates were 61.8{\%} and 54.6{\%}, respectively. Survival was related to disease stage (P G 0.0001). Among patients with advanced tumor, 5-year survival was lower in women who had macroscopic residual disease after surgery than in those who had not (15.4{\%} vs 37.5{\%}; P = 0.08). Distant failures were higher in women with histologically proven positive nodes than in those with negative nodes (28.6{\%} vs 9.1{\%}; P = 0.048). There was a trend to better survival for patients with stage I to stage II disease who underwent chemotherapy when compared with those who did not. Conclusions: Uterine papillary serous carcinoma has an aggressive clinical behavior with a great tendency to recur especially in peritoneal and distant sites. Tumor stage is a strong prognostic factor, whereas the role of adjuvant treatment is still uncertain.",
keywords = "Chemotherapy, Pattern of failure, Radiotherapy, Surgical staging, Uterine papillary serous carcinoma",
author = "Angiolo Gadducci and Stefania Cosio and Fabio Landoni and Tiziano Maggino and Paolo Zola and Luca Fuso and Enrico Sartori",
year = "2012",
doi = "10.1097/IGC.0b013e318267f7a0",
language = "English",
volume = "22",
pages = "1355--1360",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma

T2 - A cooperation task force (CTF) study

AU - Gadducci, Angiolo

AU - Cosio, Stefania

AU - Landoni, Fabio

AU - Maggino, Tiziano

AU - Zola, Paolo

AU - Fuso, Luca

AU - Sartori, Enrico

PY - 2012

Y1 - 2012

N2 - Objective: To assess the pattern of failures and the survival of patients with uterine papillary serous carcinoma (UPSC). Methods: The hospital records of 119 women with UPSC were reviewed. Surgery was the initial therapy for all the cases. The median follow-up of survivors was 133 months (range, 3Y216 months). Results: Postoperative treatment was used in 98 patients (82.4%). Adjuvant treatment was radiotherapy in 25 women, chemotherapy in 61 women, and chemotherapy plus radiotherapy in 12 women. Tumor recurred in 44 (37.0%) of the 119 patients, after a median time of 15.1 months. Relapse was symptomatic in 15 patients (34.1%), and recurrent disease involved peritoneum or distant sites in 26 (66.7%) of the 39 patients for whom the site of failure was known. Five- and 10-year survival rates were 61.8% and 54.6%, respectively. Survival was related to disease stage (P G 0.0001). Among patients with advanced tumor, 5-year survival was lower in women who had macroscopic residual disease after surgery than in those who had not (15.4% vs 37.5%; P = 0.08). Distant failures were higher in women with histologically proven positive nodes than in those with negative nodes (28.6% vs 9.1%; P = 0.048). There was a trend to better survival for patients with stage I to stage II disease who underwent chemotherapy when compared with those who did not. Conclusions: Uterine papillary serous carcinoma has an aggressive clinical behavior with a great tendency to recur especially in peritoneal and distant sites. Tumor stage is a strong prognostic factor, whereas the role of adjuvant treatment is still uncertain.

AB - Objective: To assess the pattern of failures and the survival of patients with uterine papillary serous carcinoma (UPSC). Methods: The hospital records of 119 women with UPSC were reviewed. Surgery was the initial therapy for all the cases. The median follow-up of survivors was 133 months (range, 3Y216 months). Results: Postoperative treatment was used in 98 patients (82.4%). Adjuvant treatment was radiotherapy in 25 women, chemotherapy in 61 women, and chemotherapy plus radiotherapy in 12 women. Tumor recurred in 44 (37.0%) of the 119 patients, after a median time of 15.1 months. Relapse was symptomatic in 15 patients (34.1%), and recurrent disease involved peritoneum or distant sites in 26 (66.7%) of the 39 patients for whom the site of failure was known. Five- and 10-year survival rates were 61.8% and 54.6%, respectively. Survival was related to disease stage (P G 0.0001). Among patients with advanced tumor, 5-year survival was lower in women who had macroscopic residual disease after surgery than in those who had not (15.4% vs 37.5%; P = 0.08). Distant failures were higher in women with histologically proven positive nodes than in those with negative nodes (28.6% vs 9.1%; P = 0.048). There was a trend to better survival for patients with stage I to stage II disease who underwent chemotherapy when compared with those who did not. Conclusions: Uterine papillary serous carcinoma has an aggressive clinical behavior with a great tendency to recur especially in peritoneal and distant sites. Tumor stage is a strong prognostic factor, whereas the role of adjuvant treatment is still uncertain.

KW - Chemotherapy

KW - Pattern of failure

KW - Radiotherapy

KW - Surgical staging

KW - Uterine papillary serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84867281303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867281303&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e318267f7a0

DO - 10.1097/IGC.0b013e318267f7a0

M3 - Article

C2 - 22976496

AN - SCOPUS:84867281303

VL - 22

SP - 1355

EP - 1360

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 8

ER -